Bf Biosciences Ltd · PSX:BFBIO
Bf Biosciences — Investor Presentation (November 2025)
17 slides from Bf Biosciences's investor presentation, Nov 21, 2025
Slide 1: Corporate Briefing Session
Corporate Briefing Session November 21, 2025
Slide 2: Agenda
AGENDA 1 Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session PAGE2
Slide 3: Incorporation, Founding Sponsors, Certifications, Principal Business
Incorporation Founding ISO Principle Sponsors Certifications Business Incorporated in 2006 Joint venture ISO 9001, 45000 and Primarily Engaged in as Public Unlisted between Grupo 14001 the Imports, Company, Empresarial Bagó S.A Certified. Manufacture and Subsequently listed and Ferozsons Sale of on
Slide 4: Company milestones timeline
• Financial Close of Brownfield Expansion • PESA Award • Launch of Zeptide • Start of Local (Dual GIP and GLP-1 Manufacturing • Agreement for Insulin • Implementation receptor agonist) Production with MJ Biopharm of SAP S/4 HANA 2009 2021 2023 2025 2006 2020 2023 2024 Finalization of Launch of: • BF
Slide 5: Line II facility
BIOSCIENCES Line Il PAGES.
Slide 6: Line II
Line Il
Slide 7: Agenda
AGENDA 1 Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session PAGE7
Slide 8: Existing Key Brands
BSF Existing Key Brands eee — Mh NOXANE se ENOKAPARIN Sen ARN SODTUM NTN Use BY) novanressi9 reriipressin Act y ey songton Fr sec mee ma = tea eae Oe et Ber com eter | : B = ln enrttteeernatn tad * (br Boscencer ose cereals Veen hanectirens a Eterna (ETANERCEPT) on For Sbestaneos C05 Only > axe resc
Slide 9: Recent Product Launches
Recent Product launches = BIOSCIENCES BYF of PEG, 3 b if” — F ; S = 5 — on NI HEPRIN (HEPARIN SODIUM) Injection sohion for nection ina mates va Solution for Injection 2500915 mL (500 in) 1 Ampoule eh ta | 3 ey g NOT FORLOCK FLUSH ax Ofeees Serenety (Ondansetron) exe be \ A urol (Az \ ins” = Bee Ly |
Slide 10: Agenda
AGENDA 1 Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session PAGE10
Slide 11: Pakistan's Retail Pharma Market
Overall Pakistan’s Retail Pharma Market stands at Rs. 1 Market Size 1.12 Trillion. Growth and Growth over last year stands at 17.28%, whereas last 5 2 CAGR years CAGR stands at 17.54%. Approx. 97.3% market share is held by top 100 pharma 3 Top Corporates corporates in Pakistan. Market Share Retail p
Slide 12: Agenda
AGENDA 1 Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session PAGE12
Slide 13: Income Statement FY2025
INCOME STATEMENT 7,000 FY 24 2,500 2,288 FY 24 5,837 6,000 FY 25 2,000 FY 25 5,000 1,533 PKR 5,837 Mn+ 60% 4,000 3,659 1,500 REVENUE – FY 2025 YoY 3,000 1,000 2,000 PKR 447 Mn+ 16% 500 1,000 NPAT - FY 2025 YoY 0 0 Revenue Gross Profit GROSS (Rs. Mln) (Rs. Mln) MARGIN 39% EBITDA 475 FY 24 1,200 MARGI
Slide 14: Income Statement 3MFY2026
INCOME STATEMENT 3,000 3MFY 25 1,200 1,038 3MFY 25 2,432 2,500 3MFY 26 1,000 3MFY 26 2,000 800 PKR 2,432Mn+ 75% 1,386 564 REVENUE – 3MFY 2026 YoY 1,500 600 1,000 400 PKR 160 Mn+ 38% 500 200 NPAT - 3MFY 2026 YoY 0 0 Revenue Gross Profit GROSS (Rs. Mln) (Rs. Mln) MARGIN 43% 200 400 364 3MFY 25 3MFY 25
Slide 15: Agenda
AGENDA 1 Company Profile 2 Product Portfolio 3 Pharmaceutical Industry Highlights 4 Financial Performance 5 Questions and Answers Session PAGE15
Slide 16: Questions and Answers Session
Questions and Answers Session PAGE16
Slide 17: Thank You
ime | Sanan bk Bh] iaegne THANK YOU
BF Biosciences — Investor Presentation (November 2025) on 6ix